PMID: 25787993Mar 20, 2015Paper

Isocitrate dehydrogenase mutations: new opportunities for translational research

BMB Reports
Young-Sam Keum, Bu Young Choi

Abstract

Over the last decade, comprehensive genome-wide sequencing studies have enabled us to find out unexpected genetic alterations of metabolism in cancer. An example is the identification of arginine missense mutations of isocitrate dehydrogenases-1 and -2 (IDH1/2) in glioma, acute myeloid leukemia (AML), chondrosarcomas, and cholangiocarcinoma. These alterations are closely associated with the production of a new stereospecific metabolite, (R)-2-hydroxyglutarate (R-2HG). A large number of follow-up studies have been performed to address the molecular mechanisms of IDH1/2 mutations underlying how these events contribute to malignant transformation. In the meanwhile, the development of selective mutant IDH1/2 chemical inhibitors is being actively pursued in the scientific community and pharmaceutical industry. The present review article briefly discusses the important findings that highlight the molecular mechanisms of IDH1/2 mutations in cancer and provides a current status for development of selective mutant IDH1/2 chemical inhibitors.

References

Feb 24, 1956·Science·O WARBURG
Dec 21, 2004·American Journal of Human Genetics·Eduard A StruysCornelis Jakobs
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Feb 28, 2009·The American Journal of Pathology·Takuya WatanabeHiroko Ohgaki
Apr 11, 2009·Science·Patrick J Pollard, Peter J Ratcliffe
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc SansonJean-Yves Delattre
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Dec 19, 2009·Human Mutation·Martijn KranendijkGajja S Salomons
Aug 10, 2010·Trends in Molecular Medicine·Lenny DangShinsan M Su
Sep 18, 2010·Science·Martijn KranendijkGajja S Salomons
Feb 7, 2012·Seminars in Cell & Developmental Biology·Eric K OermannYue Xiong
Jul 25, 2012·Trends in Endocrinology and Metabolism : TEM·Weibo Luo, Gregg L Semenza
Oct 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Beverly A TeicherLee J Helman
Mar 30, 2013·Science·Bert VogelsteinKenneth W Kinzler
May 1, 2013·Genes & Development·Julie-Aurore Losman, William G Kaelin
Sep 4, 2013·The Journal of Clinical Investigation·Ovidiu C AndronesiBruce R Rosen
Oct 11, 2012·ACS Medicinal Chemistry Letters·Janeta Popovici-MullerShinsan M Su

❮ Previous
Next ❯

Citations

May 28, 2017·The International Journal of Biochemistry & Cell Biology·Alison Colquhoun
Jun 2, 2016·American Society of Clinical Oncology Educational Book·John A BridgewaterMary F Mulcahy
Mar 21, 2017·BioMed Research International·Wojciech SzopaWojciech Kaspera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.